Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 17
Opinion
Video
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Author(s):
A panelist discusses how targeted gene therapy has revolutionized BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) treatment through agents like nadofaragene firadenovec, which shows promising complete response rates at 3 months, though long-term follow-up remains crucial for assessing durability of response and comparing real-world outcomes with clinical trial data.
- How has the introduction of targeted gene therapy changed the way you approach the management of BCG-unresponsive NMIBC?
- What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, and how does nadofaragene firadenovec fit into this landscape overall?
- Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
- How do these clinical trial outcomes compare with what you see in your clinical practice when treating patients with newer therapies?
- Discuss the importance of long-term follow-up for patients receiving these newer treatments.
- What is your experience in terms of durability of response?
Related Videos
Related Content
